Phylo, Inc. is an applied research lab spun out of the Stanford AI Lab, building what it calls an Integrated Biology Environment - a system designed to let biomedical scientists work alongside AI agents across the full experimental lifecycle. The team behind it pioneered foundational projects including POPPER, CRISPR-GPT, ClinicalBERT, and TxGNN, spanning drug discovery, genomics, and clinical NLP. Their first product, Biomni Lab, integrates over 300 databases, software systems, and analytical tools into a single workspace where agents assist with experiment design, dataset analysis, and result interpretation.
The technical stack sits at the intersection of agentic AI and biology: data integration pipelines, workflow automation, and autonomous agents that operate across heterogeneous scientific tooling. The threat model here isn't adversarial in the traditional cybersecurity sense - it's about reliability, reproducibility, and trust in AI-assisted scientific workflows where errors propagate through pipelines and decisions have real biological consequences.
Phylo raised $13.5M in seed funding. The company operates as a research-forward organization staffed by researchers and engineers with deep publication records in computational biology and AI. Domain work spans biomedical research, life sciences, and experimental biology - areas where data integrity and toolchain security are non-negotiable.
